Lantheus Holdings, Inc. · NASDAQ:LNTH
Lantheus — Merger or Acquisition (January 2025)
8 slides from Lantheus's merger presentation, Jan 28, 2025
Slide 1: Lantheus to Acquire Evergreen Theragnostics
© 2025 Lantheus. All rights reserved. Lantheus to Acquire Evergreen Theragnostics Solidifies Capabilities as a Fully Integrated Radiopharmaceutical Company January 28, 2025 Exhibit 99.2
Slide 2: Agenda
Acquisition Overview & Strategic Rationale Transaction Summary Manufacturing Capabilities, Pipeline and Development Platform Growth Strategy Q&A Agenda © 2025 Lantheus. All rights reserved.
Slide 3: Safe Harbor Statements
Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe h
Slide 4: Evergreen Acquisition Solidifies Radiopharmaceutical Capabilities
Evergreen Acquisition Solidifies Radiopharmaceutical Capabilities © 2025 Lantheus. All rights reserved. Solidifies capabilities across the radiopharmaceutical value chain Adds oncology therapeutic manufacturing infrastructure Strengthens clinical and commercial manufacturing capabilities OCTEVY™ reg
Slide 5: Evergreen Theragnostics: Pioneering Precision in Radiopharmaceuticals
GMP Factory Springfield, NJ Preclinical Lab Cranbury, NJ Evergreen Facilities Evergreen Theragnostics: Pioneering Precision in Radiopharmaceuticals © 2025 Lantheus. All rights reserved. Cu-64 • Ga-68 • In-111 • Pb-203 • Zr-89 • Ac-225 • At-211 • Cu-67 • I-131/I-124/I-123 • Lu-177 • Pb-212 • Tb-161 P
Slide 6: Transaction Summary: Timing and Approvals
© 2025 Lantheus. All rights reserved. Timing and Approvals Anticipated to close in the second half of 2025, subject to customary closing conditions, including regulatory clearances Transaction expectations: Accelerate & derisk critical pathways by internalizing Evergreen’s scalable manufacturing inf
Slide 7: Driving Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
Driving Strategic Evolution into Fully Integrated Radiopharmaceutical Leader © 2025 Lantheus. All rights reserved. Enhancing Lantheus’ capabilities and leadership in radiopharmaceutical innovation Scalable manufacturing platform to support development, clinical trials & commercialization efforts Abi
Slide 8: Recent Transactions will Create Long-Term Value for Shareholders
Recent Transactions will Create Long-Term Value for Shareholders © 2025 Lantheus. All rights reserved. LANTHEUS’ resources and operational & commercial expertise LMI’S & EVERGREEN’S teams, infrastructure, & capabilities UNLOCK THE full potential of our combined companies Solidifies capabilities acro
Lantheus Holdings — Merger or Acquisition (January 2025) on 6ix